Concord Biotech Ltd

Concord Biotech Limited has announced that its 41st Annual General Meeting (AGM) will be held on Friday, July 31, 2026, via Video Conferencing. The company has fixed Friday, July 24, 2026, as the record date for determining shareholders' entitlement to the final dividend for the financial year ended March 31, 2026. The register of members and share transfer books will be closed from Saturday, July 25, 2026, to Friday, July 31, 2026, inclusive. The dividend payment, if approved at the AGM, will be distributed by August 30, 2026, subject to tax deductions.

Concord Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as mandated by SEBI regulations. The report, which is part of the company's 41st Annual Report, details its operations, products, and employee data. The company's business activities primarily involve the manufacturing of pharmaceuticals, with 78.6% of turnover from Active Pharmaceutical Ingredients (APIs) and 21.4% from finished formulations. Concord serves over 300 customers in more than 70 countries, with exports contributing 46.56% to its total turnover. The report also includes details on its standalone reporting basis, reasonable assurance from its assurance provider, and contact information for queries.

Concord Biotech Limited has submitted its Annual Report for the financial year 2025-26, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report details the company's performance, corporate overview, financial statements, and management reports. It emphasizes the company's commitment to creating enduring value through innovation, operational excellence, and sustainable practices. The report covers various aspects of the company's operations, including its strategic blueprint, risk management, and value creation model across intellectual, manufactured, financial, human, natural, and social capital. It also includes the Director's Report, Corporate Governance Report, Business Responsibility & Sustainability Report, and Management Discussion & Analysis.

Concord Biotech Ltd has announced its 41st Annual General Meeting (AGM) will be held on Friday, July 31, 2026, at 12:00 Noon via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting will address ordinary business including the adoption of audited standalone and consolidated financial statements for FY 2025-26, declaration of a dividend of ₹7.55 per equity share (755%), and the re-appointment of Mr. Ankur Vaid as a director. Special business includes the appointment of Mrs. Ekta Gupta as an Independent Director. The cut-off date for voting rights and dividend entitlement is fixed as Friday, July 24, 2026.

Concord Biotech Ltd announced the successful completion of inspections by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. The inspections, conducted from June 18 to June 24, 2026, concluded successfully. This milestone is expected to strengthen Concord Biotech's global manufacturing and regulatory footprint, reinforcing its commitment to high quality and regulatory standards as part of its international growth strategy.

Concord Biotech Ltd has entered into an agreement to invest in FSGE Renewable Power Private Limited for a Wind Solar Hybrid Power Project in Gujarat. The investment involves acquiring 27.38% equity share capital in FSGE, which is setting up a 6.3 MW AC Wind and 6.3 MWp DC Solar capacity project for Concord's Limbasi Facility. This strategic move aligns with Concord's commitment to sustainability, reducing its carbon footprint, and achieving long-term financial benefits through lower energy costs. FSGE is yet to commence commercial operations, and upon acquisition, it will become an associate of Concord Biotech. The transaction is considered a Related Party Transaction but will be conducted on an arm's length basis.

Concord Biotech announced the successful completion of an ANVISA (Brazilian Health Regulatory Agency) inspection at its API manufacturing facility in Limbasi. The inspection, conducted from June 8-12, 2026, is a significant milestone for the company's global expansion. This successful audit reinforces Concord Biotech's commitment to high quality and regulatory standards, strengthens its global manufacturing and regulatory presence, and enhances its access to the Brazilian pharmaceutical market, potentially broadening the reach of its APIs globally.

Concord Biotech Ltd has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths. These tablets are indicated for treating various autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The U.S. market for Tofacitinib Tablets is estimated at approximately US$ 500 million. This approval is expected to strengthen Concord Biotech's position in the U.S. market and support its long-term growth strategy.

Concord Biotech Ltd has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This immunosuppressant is used for organ transplant recipients. The U.S. market for this drug is estimated at $30 million. This approval is expected to enhance Concord Biotech's product offerings, strengthen its market position in the U.S., and support its long-term growth strategy.

The Board of Directors of Concord Biotech Ltd has recommended a dividend of ₹7.55 per equity share with a face value of ₹1 each, fully paid up, for the financial year 2025-26, subject to shareholder approval at the upcoming AGM. The record date for dividend payment is fixed as July 24, 2026. The board also approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026, along with the Director's report. Additionally, the board approved the appointment of internal and cost auditors for the F.Y. 2026-27 and appointed Mrs. Ekta Gupta as an Additional Independent Director.